Altre lingue Arbutus Biopharma Corporation

Azioni

ABUS

CA03879J1003

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 29/11/2023			Variaz. 5gg	Var. 1 gen.
1,900 ^USD	+2,70%		+3,26%	-18,45%

09/11	Arbutus Biopharma Corporation e Barinthus Biotherapeutics plc presentano i dati preliminari dello studio clinico di Fase 2A che combina Imdusiran con VTP-300 all'AASLD	CI
07/11	Arbutus Biopharma registra una perdita netta nel terzo trimestre, un fatturato inferiore; l'amministratore delegato va in pensione, il personale di ricerca viene tagliato del 24%.	MT

Altre lingue

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Registrazione 100% gratuita

Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	09/11
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®	09/11
Arbutus to Present at Jefferies London Healthcare Conference	08/11
Arbutus to Present at Jefferies London Healthcare Conference	08/11
Arbutus Biopharma Posts Q3 Net Loss, Lower Revenue; CEO to Retire, 24% Research Staff Cut	07/11
Arbutus: Q3 Earnings Snapshot	07/11
Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q3 Revenue $4.7M, vs. Street Est of $4.7M	07/11
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update	07/11
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update	07/11
Arbutus Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Arbutus Announces CEO, William Collier, to Retire December 31, 2023	07/11
Arbutus Announces CEO, William Collier, to Retire December 31, 2023	07/11
Arbutus Biopharma Corporation Announces CEO Changes	07/11
Arbutus Biopharma Corporation Announces President Changes	07/11
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update	24/10
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update	24/10
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference	18/10
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference	18/10
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD, the Liver Meeting 2023	12/10
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023	11/10

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Transcript Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Arbutus Biopharma Corporation

Azioni

ABUS

CA03879J1003

Altre lingue

Filtri